Literature DB >> 12626204

No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice.

Mette Olesen1, Elizabeth Kwong, Arguello Meztli, Frederic Kontny, Ingebjörg Seljeflot, Harald Arnesen, Line Lyngdorf, Erling Falk.   

Abstract

OBJECTIVE: To study the role of cyclooxygenase (COX) inhibition on the development of advanced atherosclerosis in apolipoprotein E-deficient (apoE(-/-)) mice.
DESIGN: Sixty apoE(-/-) mice were divided into three groups: a control group, a group fed standard mouse chow supplemented with 0.0067% (wt/wt) MF Tricyclic (selective COX-2 inhibitor), and a group fed the diet supplemented with 0.0134% (wt/wt) sulindac (non-selective COX inhibitor). Four months later, the mice were killed and the atherosclerotic plaque area in the aortic root was measured.
RESULTS: Mean body weights did not differ at any time. The MF Tricyclic and sulindac groups had drug plasma levels of 1.31 +/- 0.11 and 0.84 +/- 0.23 micro g/ml, respectively. Plasma total cholesterol and triglyceride values were similar in all three groups. A small difference in plasma levels of high-density lipoprotein cholesterol was found between the groups (p = 0.03). Advanced atherosclerotic plaques were present in mice from all three groups, but there was no difference in mean plaque size between the groups (p = 0.9).
CONCLUSION: Neither selective COX-2 nor non-selective COX inhibition influenced the development of advanced atherosclerosis in apoE(-/-) mice.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12626204     DOI: 10.1080/140174302762659094

Source DB:  PubMed          Journal:  Scand Cardiovasc J        ISSN: 1401-7431            Impact factor:   1.589


  11 in total

Review 1.  Adventures in vascular biology: a tale of two mediators.

Authors:  S Moncada
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-05-29       Impact factor: 6.237

2.  Cyclooxygenase products and atherosclerosis.

Authors:  Macrae F Linton; Sergio Fazio
Journal:  Drug Discov Today Ther Strateg       Date:  2008

Review 3.  Cyclooxygenase-2 inhibition: vascular inflammation and cardiovascular risk.

Authors:  Francesco Cipollone; Maria Luigia Fazia
Journal:  Curr Atheroscler Rep       Date:  2006-05       Impact factor: 5.113

4.  Antagonism of the antithrombotic and anti-atherosclerotic actions of aspirin by rofecoxib in the cholesterol-fed rabbit.

Authors:  G Kaber; B Kaiser; D Baumgärtel-Allekotte; Bh Rauch; S Nossmann; Kh Heim; Aa Weber; N Nagy; Jw Fischer; K Schrör
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

5.  mRNA expression of genes involved in lipid efflux and matrix degradation in occlusive and ectatic atherosclerotic disease.

Authors:  S Soumian; R Gibbs; A Davies; C Albrecht
Journal:  J Clin Pathol       Date:  2005-12       Impact factor: 3.411

6.  Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E.

Authors:  Kathrin S Michelsen; Michelle H Wong; Prediman K Shah; Wenxuan Zhang; Juliana Yano; Terence M Doherty; Shizuo Akira; Tripathi B Rajavashisth; Moshe Arditi
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

7.  Animal models of ischemic stroke. Part one: modeling risk factors.

Authors:  Marco Bacigaluppi; Giancarlo Comi; Dirk M Hermann
Journal:  Open Neurol J       Date:  2010-06-15

8.  Absence of myeloid COX-2 attenuates acute inflammation but does not influence development of atherosclerosis in apolipoprotein E null mice.

Authors:  Ajay J Narasimha; Junji Watanabe; Tomo-o Ishikawa; Saul J Priceman; Lily Wu; Harvey R Herschman; Srinivasa T Reddy
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-11-19       Impact factor: 8.311

9.  Impact of maternal dexamethasone on coronary PGE(2) production and prostaglandin-dependent coronary reactivity.

Authors:  Robert D Roghair; Kenneth A Volk; Fred S Lamb; Jeffrey L Segar
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-07-25       Impact factor: 3.619

10.  The effects of COX-2 selective and non-selective NSAIDs on the initiation and progression of atherosclerosis in ApoE-/- mice.

Authors:  Julia Metzner; Laura Popp; Claudiu Marian; Ronald Schmidt; Christine Manderscheid; Christoph Renne; Beate Fisslthaler; Ingrid Fleming; Rudi Busse; Gerd Geisslinger; Ellen Niederberger
Journal:  J Mol Med (Berl)       Date:  2007-02-22       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.